Details
Stereochemistry | ACHIRAL |
Molecular Formula | 4Cl.Pt |
Molecular Weight | 336.896 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Cl-].[Cl-].[Pt+4]
InChI
InChIKey=FBEIPJNQGITEBL-UHFFFAOYSA-J
InChI=1S/4ClH.Pt/h4*1H;/q;;;;+4/p-4
Molecular Formula | Pt |
Molecular Weight | 195.084 |
Charge | 4 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22169035Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24515615 | https://www.ncbi.nlm.nih.gov/pubmed/19587824 | https://www.ncbi.nlm.nih.gov/pubmed/7737155 | https://www.ncbi.nlm.nih.gov/pubmed/7923207
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22169035
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24515615 | https://www.ncbi.nlm.nih.gov/pubmed/19587824 | https://www.ncbi.nlm.nih.gov/pubmed/7737155 | https://www.ncbi.nlm.nih.gov/pubmed/7923207
Diamminedichlorodihydroxyplatinum IV is the platinum-based antineoplasticis agent. Oxaliplatin is cis, cis, trans- isomer of Diamminedichlorodihydroxyplatinum IV. Oxaliplatin show high stability and therefore can be utilized orally for outpatient care. Although oxoplatin is capable of binding directly to DNA after prolonged incubation, platinum(IV) agents are considered to be largely inert prodrugs that are converted to highly cytotoxic platinum(II) compounds by reducing substances, enzymes, or microenvironmental conditions. Reaction of oxoplatin with 0.1 M hydrogen chloride mimicking gastric acid yields cis-diammine-tetrachlorido-platinum(IV) (DATCP[IV]), which exhibits two-fold increased activity. The oxoplatin metabolite DATCP(IV) constitutes a potent cytotoxic derivative that may be produced by gastric acid or acidic areas prevailing in larger solid tumors, depending on the respective pharmaceutical formulation of oxoplatin.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22169035 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Role of p38 MAPK in the selective release of IL-8 induced by chemical allergen in naive THp-1 cells. | 2008 Mar |
|
Identification of contact and respiratory sensitizers according to IL-4 receptor α expression and IL-2 production. | 2012 Apr 15 |
|
Gene expressions changes in bronchial epithelial cells: markers for respiratory sensitizers and exploration of the NRF2 pathway. | 2014 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2640563
After single i.v. administration of trans-dihydroxy-cis-dichlorodiammine-platinum(IV), the LD50 values have been calculated to range between 80 and 130 mg/kg in mice, and between 22 and 45 mg/kg in rats.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24515615
The DNA binding/capture studies were done in a total volume of 20 μL containing 38.5 μM (bp) pBR322 DNA (New EnglandBioLabs Inc.), in 12 mM HEPES, N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonicacid (pH 7.4) buffer or, when sodium bicarbonate was present, in 12 mM HEPES buffer plus 12 mM sodium bicarbonate (pH 7.4). The two reducing agents used were glutathione (GSH, 2 mM) and ascorbic acid (AsA, 50 μM). Stock solutions of the platinum compound Diamminedichlorodihydroxyplatinum IV in distilled water was in the range of 40–650 μM. Appropriate volumes of the stock solutions were added to solutions containing the buffer and DNA to give the final concentrations given earlier and values of r, where r=[platinum compound]/[DNA-bp], given in the captions to figures. The samples were incubated at 37 °C for 24 h in sealed Eppendorf tubes after which time 2.5 μL of a loading dye containing 50% glycerol, 0.25% bromophenol blue and 0.25% xylene cyanol was added. An 8 μL volume of each sample containing the loading dye was loaded in the wells of a 1% agarose gel. Electrophoresis was carried out for a period of ~4 h, at 100 V. After electrophoresis, the gel was immersed in 300 mL of deionized water containing 300 μL of a 0.5 mg/mL solution of ethidium bromide for 30 min to stain the DNA, and then soaked in water alone for 15 min to de-stain the background of the gel. A digital image of the stained gel was captured using a Kodak Gel Logic 100 imaging system equipped with Fisher Biotech IT-88A transilluminator.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:56:56 GMT 2023
by
admin
on
Sat Dec 16 08:56:56 GMT 2023
|
Record UNII |
W3YUG71TU2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000127765
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY | |||
|
236-645-1
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY | |||
|
26031
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY | |||
|
6346
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY | |||
|
Platinum(IV) chloride
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY | |||
|
DTXSID601014389
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY | |||
|
13454-96-1
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY | |||
|
SUB33877
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY | |||
|
W3YUG71TU2
Created by
admin on Sat Dec 16 08:56:56 GMT 2023 , Edited by admin on Sat Dec 16 08:56:56 GMT 2023
|
PRIMARY |